Digital Therapeutics Market Extensive Industry Analysis, Growth Rate, Segmentation, Investment Opportunities and Top Manufacturers 2035

Digital therapeutics - the increasing regulatory support has facilitated the establishment of a standard developmental pathway for these solutions The global digital therapeutics market size is estimated to grow from USD 2.31 billion in 2023 to USD 19.76 billion by 2035, representing a CAGR of 19.59% during the forecast period 2023-2035. Several organizations have undertaken diverse initiatives in the field of digital therapeutics to support its growth as a new frontier in the healthcare sector. A number of organizations focused on effectively monitoring and promoting the potential of digital therapeutics to be used as a part of strategies to improve the population health have also been established. These organizations include:  Digital Therapeutics Alliance (DTA)  Personal Connected Health (PCH) Alliance  Centers for Disease Control and Prevention (CDC)  Health Insurance Portability and Accountability Act (HIPAA)  National Health Service (NHS)  United States Food and Drug Administration (USFDA)

Leading Digital Therapeutics Companies Examples of key players engaged in digital therapeutics market (which have also been profiled in this report) include (in alphabetical order) Ampersand Health, Akili Interactives, Better Therapeutics, Brain+, Click Therapeutics, CogniFit, GAIA, Healios, JOGO Health, Jolly Good, KORE Digital Health Therapeutics, Livongo Health, Lucid, MedRhythms, Pear Therapeutics, Redicare Control, Susmed, The Learning Corp, Voluntis and WellDoc.

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections. Distribution by Type of Solution - Software Solution, Gaming Solution and Combination Solution Distribution by Type of Therapy - Curative and Preventive Distribution by Purpose of Solution - Medication Replacement and Medication Augmentation Distribution by Type of Business Model - B2B and B2C Distribution by Target Therapeutic Area - Cardiovascular Disorders, Chronic Pain, Mental Health Problems, Metabolic Disorders, Neurological Disorders Respiratory Disorders, Sleep Disorders, Substance use Disorders and Other Disorder

Key Geographical Regions - North America, Europe, Asia, Latin America, Middle East and North Africa, and Rest of the World.

Traversing a digital therapeutic from the R&D stage to the market is a long process. The various developmental stages involved in this process have been discussed in detail in the following sections.

 Discovery and Preclinical Phase: The discovery phase involves the identification of a novel digital therapeutic intervention. At this stage, researchers publish their work in academic journals and continue to investigate the potential applications of their digital solutions in disease treatment / management.

 Clinical Trials and Validation: This phase involves the conduct of proper clinical trials to validate the claims made by a digital therapeutic solution providers, and to evaluate its potential in a real-world setting. It includes testing of the software / hardware on a specific patient population. In case of clinical studies, health outcomes are measured and tracked through data driven insights provided by the software. Disease specific improvements (post application / implementation of the intervention) are also tracked to evaluate the performance of a product. There are multiple challenges associated with conducting clinical trials for digital therapeutics. Firstly, technologies are known to change rapidly and there is a very high probability for a software to undergo upgrades / improvements over the duration of a clinical trial. As a result, there are technical issues in storing and updating patient data. Secondly, digital interventions cannot be studied in a double-blind manner, because the investigator is always aware of whether a trial subject is in the control group or being treated with the intervention under evaluation. Finally, at present, there is less structure and guidelines available, and as a result meaningful and conclusive insights are difficult to be drawn from such trials.

 Negotiations with Insurance Providers / Payers: Post the successful completion of clinical studies, developer companies generally tend to avail reimbursement opportunities for their products in order to promote the use of their proprietary solutions and provide financial benefits to patients / consumers. As is the case with pharmacological interventions, reimbursement plans for these products can be achieved based on the outcomes of clinical trials and depending on the USFDA’s (or the concerned regulatory authority of a particular region) clearance. A number of health insurance providers, such as Medicare and Humana, are actively working to include digital therapeutics as a part of health insurance coverage plans for patients suffering from chronic diseases.

• Distribution and Marketing: The pharmaceutical and medical device distribution / marketing system is an established network with well-defined channels through which manufacturers can reach the end-users of their products. Product developers in this domain are presently looking to create a distribution network to sell their offerings in the market via both B2B (healthcare providers, regulators and payers) and B2C (customer) models. Thank you for reading our report. Kindly get in touch with us to know more about the report or to receive a customized copy of it. Our team will ensure the report is tailored according to your needs.

To view more details on this report, click on the link https://www.rootsanalysis.com/reports/digital-therapeutics-market/208.html About Roots Analysis Roots Analysis is a global leader in the pharma / biotech market research. Having worked with over 750 clients worldwide, including Fortune 500 companies, start-ups, academia, venture capitalists and strategic investors for more than a decade, we offer a highly analytical / data-driven perspective to a network of over 450,000 senior industry stakeholders looking for credible market insights.

We specialise in analysing areas which have lacked quality research so far or require more focused understanding within the broader industry. All our reports are structured in a way to enable the reader develop a thorough perspective on the given subject. Apart from writing reports on identified areas, we also provide bespoke research / consulting services dedicated to serve our clients in the best possible way.

The research efforts are driven by a global team. The leadership team brings a wealth of experience within the sector. Their collective experience in pharmaceutical / affiliated domains allows us to tackle various areas of research in a structured way. We also regularly leverage our global network of experts who hold senior leadership positions in reputed firms and organisations worldwide.

Contact: Roots Analysis +1 (415) 800 3415 [email protected]